LeadIQ logo
Learn more at LeadIQ.com

Insights

Gene Therapy Market Expansion Denovo Biopharma has received substantial funding and made key acquisitions, positioning itself as a prominent player in the gene therapy market. With ongoing development of novel biomarkers for gene therapy programs like DB107, there are potential sales opportunities for partnerships, collaborations, and licensing deals in this rapidly growing sector.

Companion Diagnostics Collaboration Through strategic collaborations with companies like QIAGEN, Denovo Biopharma is actively involved in developing companion diagnostics for cancer treatments. Leveraging these collaborations, there are opportunities for sales of companion diagnostic tests related to cancer therapies like Diffuse Large B-Cell Lymphoma (DLBCL) across global markets.

Biomarker-Guided Clinical Trials Denovo Biopharma's biomarker-guided trials offer a personalized medicine approach, opening avenues for sales of diagnostic services and biomarker testing solutions. The launch of biomarker-guided trials such as the TRD trial presents opportunities for partnerships with hospitals, clinics, and research institutions looking to enhance patient outcomes in treatment-resistant depression.

Regenerative Medicine Advances With significant grant financing from organizations like the California Institute for Regenerative Medicine (CIRM), Denovo Biopharma is advancing in regenerative medicine. This progress creates sales prospects in the regenerative medicine market for products like DB107 targeted towards high-grade gliomas, potentially leading to partnerships with medical institutions and healthcare providers.

Personalized Drug Development Solutions Denovo Biopharma's innovative biomarker discovery platform offers personalized solutions for drug development, catering to the increasing demand for precision medicine. Sales opportunities lie in providing tailored biomarker discovery services to pharmaceutical companies, academic researchers, and clinical trial organizations seeking to enhance drug efficacy and safety profiles in patient populations.

Similar companies to Denovo Biopharma

Denovo Biopharma Tech Stack

Denovo Biopharma uses 8 technology products and services including QuickBooks, SAS, WordPress, and more. Explore Denovo Biopharma's tech stack below.

  • QuickBooks
    Accounting And Finance
  • SAS
    Business Intelligence
  • WordPress
    Content Management System
  • MySQL
    Database
  • Google Font API
    Font Scripts
  • jQuery
    Javascript Libraries
  • DocuSign
    Miscellaneous
  • Apache
    Web Servers

Media & News

Denovo Biopharma's Email Address Formats

Denovo Biopharma uses at least 1 format(s):
Denovo Biopharma Email FormatsExamplePercentage
FLast@denovobiopharma.comJDoe@denovobiopharma.com
94%
FirstLast@denovobiopharma.comJohnDoe@denovobiopharma.com
3%
Last@denovobiopharma.comDoe@denovobiopharma.com
2%
FirLast@denovobiopharma.comJohDoe@denovobiopharma.com
1%

Frequently Asked Questions

Where is Denovo Biopharma's headquarters located?

Minus sign iconPlus sign icon
Denovo Biopharma's main headquarters is located at 10240 Science Center Dr San Diego, California 92121 US. The company has employees across 2 continents, including North AmericaAsia.

What is Denovo Biopharma's phone number?

Minus sign iconPlus sign icon
You can contact Denovo Biopharma's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Denovo Biopharma's official website and social media links?

Minus sign iconPlus sign icon
Denovo Biopharma's official website is denovobiopharma.com and has social profiles on LinkedIn.

How much revenue does Denovo Biopharma generate?

Minus sign iconPlus sign icon
As of September 2024, Denovo Biopharma's annual revenue reached $3.8M.

What is Denovo Biopharma's SIC code NAICS code?

Minus sign iconPlus sign icon
Denovo Biopharma's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Denovo Biopharma have currently?

Minus sign iconPlus sign icon
As of September 2024, Denovo Biopharma has approximately 32 employees across 2 continents, including North AmericaAsia. Key team members include Chief Business Officer And Head Of Us Finance: M. H.Chief Business Officer, Denovo Biomarkers: R. L.Chief Operating Officer: X. F.. Explore Denovo Biopharma's employee directory with LeadIQ.

What industry does Denovo Biopharma belong to?

Minus sign iconPlus sign icon
Denovo Biopharma operates in the Biotechnology Research industry.

What technology does Denovo Biopharma use?

Minus sign iconPlus sign icon
Denovo Biopharma's tech stack includes QuickBooksSASWordPressMySQLGoogle Font APIjQueryDocuSignApache.

What is Denovo Biopharma's email format?

Minus sign iconPlus sign icon
Denovo Biopharma's email format typically follows the pattern of . Find more Denovo Biopharma email formats with LeadIQ.

How much funding has Denovo Biopharma raised to date?

Minus sign iconPlus sign icon
As of September 2024, Denovo Biopharma has raised $12M in funding. The last funding round occurred on Apr 30, 2024 for $12M.

When was Denovo Biopharma founded?

Minus sign iconPlus sign icon
Denovo Biopharma was founded in 2011.
Denovo Biopharma

Denovo Biopharma

Biotechnology ResearchCalifornia, United States11-50 Employees

A Novel Biomarker Discovery Solution for Personalized Drug Development 

Denovo Biopharma is a private San Diego based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects. By identifying biomarkers correlated to patients'​ responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in most therapeutic areas, such as oncology and neurological diseases.

Section iconCompany Overview

Headquarters
10240 Science Center Dr San Diego, California 92121 US
Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
11-50

Section iconFunding & Financials

  • $12M

    Denovo Biopharma has raised a total of $12M of funding over 5 rounds. Their latest funding round was raised on Apr 30, 2024 in the amount of $12M.

  • $10M

    Denovo Biopharma's revenue is in the range of $10M

Section iconFunding & Financials

  • $12M

    Denovo Biopharma has raised a total of $12M of funding over 5 rounds. Their latest funding round was raised on Apr 30, 2024 in the amount of $12M.

  • $10M

    Denovo Biopharma's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.